Cabozantinib- API Insight, 2018

Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL...

Read More

Myelodysplastic Syndromes (MDS) – Epidemiology Insights (2016-2028)

Myelodysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity. This syndrome can be...

Read More

Uveal Melanoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations

Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body. The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia....

Read More

Tuberous Sclerosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

Tuberous sclerosis, also known as tuberous sclerosis complex, is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. It can occur in the brain, skin, kidneys, and other organs, in some cases leading to significant...

Read More

Thymic Carcinoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations

Thymic carcinoma, also known as thymomas, is a rare type of cancer that forms in the cells present in the outside surface of the thymus. Thymus is a small organ that lies in the upper chest under the breastbone. It is a part of the lymph system and produces certain types of...

Read More

Sezary Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

Sézary syndrome, a type of cutaneous T-cell lymphoma, affects Sézary cells present in the skin, lymph nodes and blood. It accounts approximately 3 to 5 percent of cases of cutaneous T-cell lymphoma. Sézary syndrome is more prevalent in males compared to females. It is...

Read More

Pontine Glioma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Pontine glioma is more prevalent in children than adults. The common signs and...

Read More

Juvenile Myelomonocytic Leukemia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents

Juvenile myelomonocytic leukemia is a rare disease that occurs mostly in the children who are under four years of age. The abnormal growth of the monocytes results in the accumulation of monocytes in the bone marrow. This leads to improper functioning of the bone marrow. The...

Read More

Hormone Sensitive Breast Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations

Breast cancer generally occurs when breast cells grow uncontrollably. Mostly, breast cancer development starts in the duct that carries milk to the nipples. Some breast cancer cells develop in milk producing glands. As per the National Institutes of Health (NIH), in the U.S.,...

Read More

Gorlin Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

Gorlin syndrome, also known as basal cell nevus syndrome, is an inherited genetic disorder characterized by multiple basal cell skin cancer. The common symptoms observed during Gorlin syndrome are calcium deposition in brain, jaw cysts, skeletal changes and developmental...

Read More

Angiopoietin (ANG) Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations

Angiopoietin (ANG) receptor plays a crucial role in regulation of vascular permeability and pathological vascular remodelling during tumour angiogenesis, metastasis and inflammation. Thus, it has emerged as a new clinical approach for the development of therapeutics which...

Read More

Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents

Spleen tyrosine kinase (Syk) is a protein that belongs to the family of tyrosine kinases with an ability to initiate the inflammatory responses, by connecting immune cell receptors to intracellular signaling pathways. Therefore, Syk is an attractive target for improving the...

Read More

Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results

Glycogen synthase kinase 3 beta (GSK-3β) is an attractive target for the treatment of psychiatric disorders and neurodegenerative diseases. Many GSK-3β inhibitors have been developed for the treatment of different central nervous system disorders. But, for an effective therapy,...

Read More

Bone Metastases Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents

Bone metastases is a common form of cancer of the skeleton that inhabits in bone marrow and stimulates the local bone activity. In this condition, the normal bone homeostasis disrupts which leads to the development of the tumour. Some of the major symptoms observed in patients...

Read More

Acquired Immunodeficiency Syndrome (AIDS) Related Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

Acquired immunodeficiency syndrome (AIDS) related cancer include those types of cancer which occurs in patients suffering from AIDS. People with AIDS are reported to be highly suspected to the occurrence of lymphomas. According to the American Society of Clinical Oncology, Kaposi...

Read More